Radiopharma: Pluvicto, Telix, and the $8B Isotope Moat

The $8 billion Curium-Lantheus deal was the signal radiopharma stopped being a footnote. It is the largest radiopharmaceutical acquisition in history, eclipsing Bristol Myers Squibb’s $4.1 billion RayzeBio deal and AstraZeneca’s $2.4 billion Fusion pickup. When private equity pays up for a diagnostics-and-therapeutics company, the sector has graduated from niche to a core oncology vertical. (the Curium Lantheus deal).

The mechanism explains the excitement. Radioligand therapy attaches a targeting molecule, PSMA or SSTR2, to a radioisotope, lutetium-177 or actinium-225, and delivers radiation straight to tumor cells. It is precision radiotherapy, not chemo. The same target can be imaged first with a PET agent, then irradiated with a therapeutic isotope, which is why radiopharma bridges diagnostics and oncology. That pairing, called theranostics, is the moat.

Here is how the investable plays rank. Prices are Polygon’s August 21 close.

1. Novartis (NVS): Pluvicto and the Franchise No One Can Catch

NVS closed at $158.86 with roughly a $300 billion market cap. Pluvicto is the franchise. The FDA approved it for metastatic hormone-sensitive prostate cancer on July 31, 13 days early, moving the drug into first-line metastatic disease. (Pluvicto mHSPC approval).

The Phase 3 PSMAddition trial (NCT04720157) enrolled 1,144 patients and showed a 28% reduction in risk of radiographic progression or death: rPFS hazard ratio 0.72, p=0.002. Overall survival is trending favorably but immature (HR 0.84), and complete response rates were 57.1% versus 42.3% for standard of care, at the cost of a higher Grade 3-plus adverse event rate of 50.7% versus 43%. The hormone-sensitive population is roughly four times larger than the castration-resistant setting, with about 172,000 men diagnosed annually across major markets. Pluvicto did $651 million in Q2, up 43%, a $2.6 billion run rate, and the combined radiopharma franchise with Lutathera is at $3.5 billion annualized. (Novartis radiopharma franchise analysis). The global radiopharmaceutical market was valued at $14.2 billion in 2026 and is projected to reach $31 billion by 2032, so Novartis’s run rate is roughly 25% market share with no competitor close.

At a $300 billion market cap, radiopharma is about 6% of revenue, so the approval adds maybe 4% of upside. The stock is a Hold, but it is the only large cap with real radiopharma revenue, and it owns the isotope problem better than anyone. The next catalyst, 225Ac-PSMA-617 Phase 3 data for post-lutetium patients, is 2027 to 2028.

2. Lantheus (LNTH): The Takeout Is Priced

LNTH closed at $99.97, just under the $102.50 upfront cash Curium agreed to pay, with up to $12 more in contingent value rights tied to milestones through 2030. The $8 billion total values the deal at a 38% premium to the 60-day average. The trade is done: Lantheus is a takeout arbitrage, not a standalone thesis. PYLARIFY revenue was already declining 6.5% year over year under generic Ga-68 pressure. There is little left here except to collect the spread. Hold if you own it; do not chase.

3. Telix (TLX): The Revenue-Generating Pure Play

Telix is the cleanest way to own radiopharma growth without the mega-cap dilution. The ADR trades around $12.42 with roughly a $4.2 billion market cap. The company generated $247 million in Q2 revenue, up 21% year over year, and $477 million in the first half, on sales of its PSMA-PET imaging agent Illuccix, with volume up 27%, plus the newly launched Gozellix. Full-year guidance is $950 million to $970 million.

Telix is the theranostics thesis in action: it owns the imaging side today and is building the therapeutic side. Telix is also a cleaner comp to Lantheus than most investors realize. Both sell PSMA-PET imaging, but Telix is growing volume 27% while Lantheus’s PYLARIFY shrank 6.5% under generic pressure. The difference is pipeline depth: Telix’s therapeutic programs give it a path from imaging into therapy, which is the arc Lantheus never completed on its own. The risk is that imaging agents face the same generic and academic-center pressure that hit PYLARIFY, and the therapeutic pipeline is earlier stage. But at $4.2 billion for a business doing nearly $1 billion in revenue growing 20% plus, Telix is the most direct pure play. This is the Buy in the sector.

4. Perspective Therapeutics (CATX): The Alpha Bet

CATX closed around $3.48 with a $397 million market cap. Perspective is the speculative alpha play: it uses lead-212, an alpha-emitting isotope that deposits energy over 2 to 10 cell diameters versus beta particles that travel 50 to 100. That precision is the theoretical edge, and Novartis’s own next-gen asset, 225Ac-PSMA-617, validates the alpha thesis. Perspective is dosing patients in Phase 1/2a across neuroendocrine tumors and melanoma. It is pre-revenue, early stage, and binary. A lottery ticket, not an investment. Only for risk capital.

The Isotope Moat

The real bottleneck is supply, not demand. Lutetium-177 requires isotopically enriched targets, high-flux neutron reactors, and weeks-long irradiation cycles. Actinium-225 is even scarcer: it is produced through decay of thorium-229 recovered from Department of Energy stockpiles, with TerraPower Isotopes and NorthStar Medical Radioisotopes racing to add capacity. Because isotopes decay, there is no inventory; every dose must be produced, quality-checked, and shipped on a tight schedule. (BioSpace on the actinium-225 supply race).

That is why the Curium deal matters more than its price. Curium brings global manufacturing across 70-plus countries. Lantheus brings US commercial infrastructure. Together they control a bigger slice of a supply chain that is already the sector’s hard ceiling. The companies that own isotope production will own the margins, and that is a moat ordinary small molecules cannot copy. The economics tilt toward radiopharma too. Because companion PET imaging pre-selects patients who express the target, trials enroll responders and can read out faster and cheaper than a traditional oncology study. Novartis generates $3.5 billion in annual radiopharma revenue from two approved drugs, while AstraZeneca paid $2.4 billion for Fusion, a pre-revenue company with no approved products. That gap is proof the market pays a premium for an operating theranostics franchise. For how theranostic pairing shapes regulatory approval, see the PET imaging and companion diagnostics guide.

Risks

The manufacturing risk is the one investors underprice. ITM’s 177Lu-edotreotide was handed a complete response letter on manufacturing and facility findings alone, no clinical issues, because a third-party facility inspection failed. Radiopharma carries a manufacturing risk ordinary small molecules do not, and a single facility finding can stall an otherwise approvable drug. Even the leader is capacity-constrained. Novartis runs radioligand production sites in Millburn, Zaragoza, and Ivrea, with a new Indianapolis facility online and expansions in Carlsbad and Sasayama, and scaling that network to a patient pool four times larger will take years.

The clinical risk is alpha versus beta. Alpha-emitting therapies have not yet proven durable survival benefit in a registrational trial. Novartis’s 225Ac-PSMA-617 and Perspective’s lead-212 program are both betting that the physics translates to better outcomes, and that data is years away.

The competitive risk is that Novartis already owns the PSMA market. Every other company is fighting for the crumbs or the next isotope. That concentration is good for Novartis and bad for everyone else.

The Ranking

1. TLX Telix: the revenue-generating pure play at roughly 4x forward sales with a theranostics pipeline. Buy.
2. NVS Novartis: owns the category and the isotope problem, but a $300 billion stock will not move on one drug. Hold, buy on pullbacks.
3. LNTH Lantheus: a takeout arbitrage with the spread mostly closed. Hold.
4. CATX Perspective: a pre-revenue alpha lottery ticket. Avoid unless you want a small speculative position.

The takeaway: radiopharma is real, but the value is split between the mega-cap that owns the market and the pure play that owns the growth. Buy Telix for the torque, hold Novartis for the franchise, and treat the alpha names as lottery tickets. The isotope moat is the reason the Curium deal happened, and it is the reason the winners will keep winning.